Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Apr 29, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

1.0K

Identification of Prognostic Risk Factors in Older Patients With Extensive-Stage Small Cell Lung Cancer.

Jiayin Liu1, Xun Liu1, Xiaolin Li1,2

  • 1Department of Medical Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.

Cancer Medicine
|April 27, 2026
PubMed
Summary

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

862
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
862

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combined Lorlatinib, Dabrafenib, and Trametinib Treatment for <i>ROS1</i>-Rearranged Advanced Non-Small-Cell Lung Cancer with a Lorlatinib-Induced <i>BRAF</i> V600E Mutation: A Case Report.

Cancer management and research·2022
Same author

Bifidobacterium breve predicts the efficacy of anti-PD-1 immunotherapy combined with chemotherapy in Chinese NSCLC patients.

Cancer medicine·2022
Same author

The Prognostic Value of Baseline Distant Metastasis in Icotinib-Treated Patients with <i>EGFR</i>-Mutated Stage IV Non-Small Cell Lung Cancer.

Cancer management and research·2021
Same author

High mobility group box 1 (HMGB1) levels in the placenta and in serum in preeclampsia.

American journal of reproductive immunology (New York, N.Y. : 1989)·2011
Same author

Destabilization of coxsackievirus b3 genome integrated with enhanced green fluorescent protein gene.

Intervirology·2011
Same author

[Clinicopathological features of primary splenic histiocytic sarcoma: a case report and literature review].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi·2011

This study confirms that age, chemotherapy, smoking history, bone metastasis, high lactate dehydrogenase, and pro-gastrin-releasing peptide levels are key prognostic factors for older patients with extensive-stage small cell lung cancer (ES-SCLC). Pro-gastrin-releasing peptide

Area of Science:

  • Oncology
  • Geriatric Medicine
  • Clinical Research

Background:

  • Limited evidence exists on prognostic factors for older patients with extensive-stage small cell lung cancer (ES-SCLC).
  • Older patients represent a distinct clinical subgroup requiring tailored prognostic assessments.
  • Previous prognostic indicators need validation in this specific vulnerable population.

Purpose of the Study:

  • To validate established prognostic indicators in older patients with ES-SCLC.
  • To identify specific prognostic factors influencing progression-free survival (PFS) and overall survival (OS) in this cohort.
  • To investigate the time-dependent prognostic impact of pro-gastrin-releasing peptide (ProGRP) in older ES-SCLC patients.

Main Methods:

  • Retrospective analysis of 270 older ES-SCLC patients treated between December 2016 and June 2024.
Keywords:
extensive‐stage small cell lung cancerolder patientsprognostic risk factorssurvival

Related Experiment Videos

Last Updated: Apr 29, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

1.0K
  • Utilized univariate and multivariate Cox regression analyses to identify independent prognostic factors for PFS and OS.
  • Assessed the time-dependent prognostic significance of high pro-gastrin-releasing peptide (ProGRP) levels.

    • Main Results:

    • First-line chemotherapy (CT) and being "old-old" (≥75 years) were independent adverse prognostic factors for PFS.
    • For OS, "old-old" status, positive smoking history, bone metastasis, and high lactate dehydrogenase (>250 U/L) were significant adverse prognostic factors.
    • High ProGRP (>69.2 pg/mL) showed a time-dependent association with increased mortality risk beyond 10 months (HR=1.85).

    Conclusions:

    • Previously identified risk factors retain prognostic value in older ES-SCLC patients.
    • Age, treatment, smoking history, metastasis, LDH, and ProGRP are crucial for prognosis in this group.
    • The prognostic impact of ProGRP is time-dependent, becoming significant after the initial 10 months of follow-up.